PMGC Holdings Inc. (ELAB)
NASDAQ: ELAB · Real-Time Price · USD
5.72
-8.28 (-59.14%)
At close: Apr 2, 2026, 4:00 PM EDT
4.730
-0.990 (-17.31%)
After-hours: Apr 2, 2026, 7:59 PM EDT
PMGC Holdings Revenue
In the year 2025, PMGC Holdings had annual revenue of $590.08K. PMGC Holdings had revenue of $304.14K in the quarter ending December 31, 2025.
Revenue (ttm)
$590.08K
Revenue Growth
n/a
P/S Ratio
5.25
Revenue / Employee
$196,695
Employees
3
Market Cap
3.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 590.08K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 766.28K | 765.45K | 92,557.44% |
| Dec 31, 2021 | 827.00 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionELAB News
- 1 day ago - PMGC Holdings Inc. Announces the Formation of New Subsidiary, NorthStrive Defense Tech to Target High-Growth Defense, Drone and Autonomous Systems Sector - GlobeNewsWire
- 3 days ago - AGA Precision Systems Signs Long-Term Agreement to Supply Mission-Critical Aerospace and Defense Components to Turbo-Jet Products - GlobeNewsWire
- 4 days ago - PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024 - GlobeNewsWire
- 10 days ago - SVM Machining, Inc. Secures ITAR Registration, Enabling Entry into U.S. Defense Manufacturing Contracts - GlobeNewsWire
- 24 days ago - NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy - GlobeNewsWire
- 4 weeks ago - PMGC Holdings Inc. Announces Anticipated Reverse Stock Split - GlobeNewsWire
- 6 weeks ago - NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals - GlobeNewsWire
- 7 weeks ago - NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health - GlobeNewsWire